SCHEMBL1600188

SCHEMBL1600188

c1ccc(-c2nnc3ccc4cc(Sc5cccc(C6(OCC7CC7)CCOCC6)c5)ccc4n23)cc1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
LRRK2 Q5S007 2/20 0.33
THRB P10828 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ALOX5 P09917 7/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPT P10636 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1599824 0.87 ALOX5 (0.40) RECQLKDM4EALDH1A1LMNAHPGD
SCHEMBL1598884 0.82 RECQL (0.37) RECQLKDM4EALDH1A1LMNAHPGD
SCHEMBL1599056 0.80 PIK3CD (0.38) RECQLKDM4EALDH1A1LMNAHPGD
SCHEMBL1599252 0.78 ALOX5 (0.52) RECQLKDM4EALDH1A1LMNAHPGD
SCHEMBL1599093 0.74 PIK3CD (0.36) RECQLKDM4EALDH1A1LMNAHPGD
SCHEMBL1599196 0.73 LRRK2 (0.40) RECQLKDM4EALDH1A1LMNAHPGD
SCHEMBL1599189 0.73 LRRK2 (0.37) RECQLKDM4EALDH1A1LMNAHPGD
SCHEMBL1599048 0.73 KMT2A (0.37) RECQLKDM4EALDH1A1LMNAHPGD
SCHEMBL1598275 0.72 RECQL (0.34) RECQLKDM4EALDH1A1LMNAHPGD
SCHEMBL1598951 0.72 PIK3CD (0.38) RECQLKDM4EALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112106-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2011-05-12 US claimed
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2007-07-26 US claimed
US-20110112106-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2011-05-12 US disclosed
US-7919621-B2 Tricyclic inhibitors of 5-lipoxygenase AMIRA PHARMACEUTICALS, INC. (US) 2011-04-05 US disclosed
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE ALOX5, ALOX15, ALOX15B RECQL 1884/4885KDM4E 2132/4885ALDH1A1 802/4885
US-20110112106-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE ALOX5, ALOX15, ALOX15B RECQL 1884/4885KDM4E 2132/4885ALDH1A1 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.